Life Sciences & Healthcare  Newsletters

Kempen European Life Sciences ECM update 

  • Monthly update on Equity Capital Markets of European Life Sciences companies
  • Provides insights on market developments, financing transactions, share price developments and other relevant insights in the field of ECM
  • Example analysis from the February 2018 ECM update below

Origin of European Life Sciences companies that IPO’d on a US capital market in the last 5 years

ECM update April 2018

  • Over the last 5 years, 25 European Life Sciences companies (excl. UK) obtained a listing in the US1
  • 15 European Life Sciences companies sought a direct listing in the US, while 10 companies obtained a listing in the US after already being listed on a European stock exchange (i.e. secondary listing)
  • Benelux companies represented the majority of companies that went public in the US (9 companies), followed by Denmark and France (both 4 companies)


* Includes the NASDAQ Global Select and NASDAQ Global Market; includes direct and secondary listings
Source: Dealogic

 

 

Kempen European Life Sciences M&A update 

  • Bi-monthly update on Mergers & Acquisitions of European Life Sciences companies
  • Provides insights on the current M&A climate, recent developments, transactions and other relevant insights in the field of M&A 
  • Example analysis from the November 2017 M&A update below

Red hot European Life Sciences M&A market in 2017

Red Hot European Life Sciences in 2017  

  • In total, 140 European linked* Life Sciences transactions were announced in 2017
  • North America based companies were the most active acquirers, with 30 announced transactions; in Europe, UK companies were the most active acquirers with 20 announced transactions
  • Canada and US based companies were also the most targeted companies, with 39 announced transactions by a European acquirer
  • In the Benelux, the UK and Asia, many more companies were acquirer than target; in Germany, North America and Spain and Portugal more companies were targets than acquirers

* i.e. transactions involving a European target, a European acquirer, or both

Subscribe now

Leave your company email address here to receive our Life Sciences & Healthcare Newsletters